Inactive Instrument

Other languages Biofrontera AG OTC Markets

Equities

Biofrontera Announces the Launch of A New, FDA-Approved Red Light Source, the RhodoLED® XL Lamp	Jun. 24
Biofrontera AG Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 31
Biofrontera : Quartalsmitteilung zum 1. Quartal Q1/2024	May. 31
Biofrontera : GESCHÄFTSORDNUNG FÜR DEN AUFSICHTSRAT	May. 27
Biofrontera : Leonteq Securities AG - Aufhebung der Zulassung zum Handel (Sponsored Segment)	May. 14
Biofrontera : Bezugsangebot	May. 07
Biofrontera : Announcement of capital reduction (German only)	May. 07
Biofrontera AG Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 30
Biofrontera : Jahresfinanzbericht 2023 nach HGB	Apr. 30
Biofrontera : Abstimmungsergebnisse	Apr. 03
Biofrontera Files Prospectus for Potential Secondary Stock Offerings	Mar. 11
MORNING BRIEFING - Deutschland/Europa -2-	Feb. 16
Biofrontera AG Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 28
Biofrontera Licensor Gets FDA Approval for New Formulation of Ameluz to Treat Actinic Keratosis	23-10-10
Biofrontera AG Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-31
Biofrontera Says Skin Disease Therapy Was Well-Tolerated in Phase 1 Safety Trial	23-08-28
Biofrontera Completes Patient Enrollment in Skin Cancer Treatment Study	23-08-10
Top Premarket Decliners	23-07-21
Biofrontera Launches Novel Belixos Active Care	23-07-05
Biofrontera to Effect 1-for-20 Reverse Stock Split	23-07-03

No results for this search